Odronextamab Monotherapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: Primary Efficacy and Safety Analysis in Phase 2 ELM-2 Trial
Academic Background Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive form of B-cell non-Hodgkin lymphoma (B-NHL), accounting for approximately 30% of all non-Hodgkin lymphomas. Although first-line immunochemotherapy (e.g., R-CHOP regimen) has shown efficacy in DLBCL patients, about 30% of patients relapse or become refractory (relapsed/refrac...